Sergio Traversa - 30 Jun 2022 Form 4 Insider Report for RELMADA THERAPEUTICS, INC. (RLMD)

Role: Chief Executive Officer, Director
Signature: /s/ Sergio Traversa
Issuer symbol: RLMD
Transactions as of: 30 Jun 2022
Net transactions value: -$83,305
Form type: 4
Filing time: 05 Jul 2022, 16:30:38 UTC
Previous filing: 26 May 2022
Next filing: 12 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RLMD	Common Stock	Options Exercise	$256,192	+16,012	+18%	$16.00^*	104,786	30 Jun 2022	Direct	F1
transaction	RLMD	Common Stock	Sale	$102,932	-5,314	-5.1%	$19.37^*	99,472	30 Jun 2022	Direct	F2, F3
transaction	RLMD	Common Stock	Sale	$203,369	-10,698	-11%	$19.01^*	88,774	30 Jun 2022	Direct	F2, F4
transaction	RLMD	Common Stock	Options Exercise	$220,080	+13,755	+15%	$16.00^*	102,529	01 Jul 2022	Direct	F1
transaction	RLMD	Common Stock	Sale	$15,505	-839	-0.82%	$18.48^*	101,690	01 Jul 2022	Direct	F2, F5
transaction	RLMD	Common Stock	Sale	$163,246	-8,848	-8.7%	$18.45^*	92,842	01 Jul 2022	Direct	F2, F6
transaction	RLMD	Common Stock	Sale	$74,526	-4,068	-4.4%	$18.32^*	88,774	01 Jul 2022	Direct	F2, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RLMD	Stock Option (right to buy)	Options Exercise	$0	-16,012	-54%	$0.000000	13,755	30 Jun 2022	Common Stock	16,012	$16.00	Direct	F1, F8
transaction	RLMD	Stock Option (right to buy)	Options Exercise	$0	-13,755	-100%	$0.000000^*	0	01 Jul 2022	Common Stock	13,755	$16.00	Direct	F1, F8

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this Form 4 reflects the exercise of stock options set to expire on July 10, 2022.
F2	The number of securities reported represents an aggregate number of shares sold in multiple open market transactions over a range of sales prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares sold by the Reporting Person at each separate price within the range.
F3	Sales prices range from $19.20 to $19.51 per share, inclusive.
F4	Sales prices range from $19.00 to $19.15 per share, inclusive.
F5	Sales prices range from $18.47 to $18.53 per share, inclusive.
F6	Sales prices range from $18.45 to $18.47 per share, inclusive.
F7	Sales prices range from $18.26 to $18.44 per share, inclusive.
F8	The options were granted on July 10, 2012 (the "Grant Date"). 25% of the options vested upon the Grant Date and the remaining 75% of the options vested in equal quarterly increments over the next four (4) years, so that the last set of options vested in July 2016.